COSM

Cosmos Holdings Inc. 10-K Summary (Fiscal Year Ended Dec 31, 2018)

Business Context and Reporting Period

Cosmos Holdings Inc. (ticker: COSM) is a multinational pharmaceutical wholesaler operating primarily in the European Union through wholly-owned subsidiaries SkyPharm SA (Greece), Decahedron Ltd (UK), and Cosmofarm Ltd (Greece, acquired Dec 2018). The company imports, exports, and distributes branded and generic pharmaceuticals, OTC medicines, and dietary supplements. The reporting period covers the fiscal year ended December 31, 2018. The company is classified as a "Smaller Reporting Company."

Key Financial Metrics

Note: Total debt includes Notes Payable ($9.8M), Convertible Notes ($0.1M), Lines of Credit ($1.5M), and Related Party Loans ($1.8M).

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased 24% year-over-year, driven by organic growth in SkyPharm and Decahedron operations.
• Operating Expenses: Operating expenses decreased approximately 47% compared to 2017. This reduction is primarily due to the absence of a $1.95 million goodwill impairment charge recorded in 2017 related to the Decahedron acquisition and a 78% decrease in consulting expenses.
• Net Loss Increase: Despite lower operating expenses, the net loss increased by 46% to $9.06 million. This was driven by significant non-cash interest expenses ($5.84 million) related to warrant fair value, debt extinguishment, and amortization of debt discounts, as well as a $1.94 million debt modification expense.
• Acquisitions: Completed the acquisition of Cosmofarm Ltd in December 2018 for a purchase price of €200,000 (promissory note), expanding full-line wholesale distribution in Greece.
• Divestiture: Sold 100% of its subsidiary Amplerissimo Ltd in September 2018 for €5,000, recording a gain of $146,647.

Guidance, Outlook, Risks, and Contingencies

• Going Concern: The company has an accumulated deficit of $16.27 million and a working capital deficit of $3.93 million. Management states that the ability to continue as a going concern is dependent on obtaining adequate capital to fund operating losses. The auditor has issued a "Going Concern" opinion.
• Strategy: Focus remains on expanding pharmaceutical trading, launching the "Sky Life Premium" nutraceutical brand (sales began Q4 2018), and exploring cannabis derivative distribution in the EU (pending regulatory clarity).
• Debt Obligations: The company holds significant debt, including Senior Convertible Notes and trade facilities with Synthesis Structured Commodity Trade Finance Limited. Many debt instruments contain complex terms, including conversion features, warrants, and personal guarantees by CEO Grigorios Siokas.
• Related Party Transactions: Significant transactions exist with related parties, including Doc Pharma S.A. (CEO's wife is CEO of Doc Pharma) and Medihelm S.A. (Managing Director is mother of UK subsidiary's MD). These entities account for a substantial portion of purchases and prepayments.
• Internal Controls: Management identified a material weakness in internal controls over financial reporting due to a lack of segregation of duties and insufficient review levels.

Investor Verification Checklist

• Liquidity Runway: Verify if the company has secured the additional financing required to cover the $3.9M working capital deficit and fund operations for the next 12 months.
• Debt Covenants: Review the specific covenants and maturity dates of the Synthesis trade facilities and Senior Convertible Notes to assess immediate refinancing or default risks.
• Related Party Pricing: Scrutinize the pricing and terms of transactions with Doc Pharma S.A. and Medihelm S.A. to ensure they are at arm's length.
• Revenue Quality: Confirm the sustainability of the 24% revenue growth and the collectability of the $4.75M accounts receivable balance.
• Internal Control Remediation: Assess the timeline and progress for hiring additional staff to remedy the material weakness in internal controls.